



Maternal Serum Screening

Delivers Clarity and Reassurance for Healthy Outcome

Prenatal Screening Solutions

- Analysis of biochemical markers along with ultrasonographic findings is ideally performed between 11-13 weeks in 1st trimester & between 15-21 weeks in 2nd trimester.
- MedGenome utilizes Fetal Medicine Foundation (FMF UK) approved DELFIA® technology using Life cycle software, a clinically validated platform configured as per population data.
- DELFIA is one of the only four biochemistry analyzers certified by FMF.
- As per clinical research, non-FMF certified assays lower the detection rate and increase the false positive rate leading to more invasive testing.
- Multiple of medians (MoMs) have been validated with indigenous population data.
- CAP Accredited.

Reflex NIPT

Patients in the high risk category can choose to go with Reflex NIPT test which provides a **safe, accessible, accurate, non-invasive** modality with >99% detection rate and false positive rate of 0.3%. Less than 0.5% of cases need to go for invasive testing post NIPT, as per published literature.

Pioneer in the field of NIPT (CAP accredited) since 2017

Note: NIPT is done only if the marker test is High Risk

Free Pre & Post test Genetic counseling sessions with our experts

Facts about Maternal Serum Screening



The risk calculation requires Nuchal Translucency (NT), Nasal Bone (NB) & Biparietal Diameter (BPD), measurements should be performed by a certified ultrasonographer.



Mandatory information required for accurate risk calculation using the software: Calculated gestational age, number of foetuses, patient weight, height, ethnicity, and family history.



First trimester screening doesn't evaluate the risk of neural tube defects. Second Trimester /Quadruple screen can be done for the same after 15 weeks.



It also requires history of insulin & non-insulin dependent diabetes mellitus (NIDDM) and smoking. For IVF patients, the source of egg (patient or donor), patient age at egg retrieval and the date of egg extraction will also be required.

Interpretation of Results

Detection rate is 87-90% in first trimester and 72-83% in second trimester. In practice, both the detection rate and false-positive rate increase with age, thus detection and positive rates will vary depending on the age distribution of the screening population.

Test Details

Test code	Name	Markers	Gestation in weeks	TAT*
MGM2445	First Trimester screening	Free βHCG, PAPP-A	11w-13w ^{+6days} with NT/ 9w-13w ^{+6days} without NT	1 day
MGM2447	First Trimester screening with Pre-eclampsia risk	Free βHCG, PAPP-A, PIGF	11w-13w ^{+6days}	1 day
MGM2448	First trimester screening with Reflex NIPT Test	Free β HCG, PAPP-A ^{+NIPT}	11w-13w ^{+6days}	1 day+ 10 days
MGM2446	Quadruple screening	AFP, Free βHCG, UE3, Inhibin A	15w-21w+6days	1 day
MGM2449	Quadruple test with Reflex NIPT	AFP, Free β HCG, UE3, Inhibin A ^{+NIPT}	15w-21w ^{+6days}	1 day + 10 days
MGM2465	Enhanced - First Trimester Quadruple Screening with Pre-eclampsia	Free βHCG, PAPP-A, AFP, PIGF	11w-13w ^{+6 days}	1 day
MGM 2469	Triple Marker screening	AFP, Free β HCG, UE3	15w-21w ^{+6 days}	1 day

*after receipt in the lab. Applicable for lab working days and not on approved holidays

Reference

arter receipt in the lab. Applicable for lab working days and not on approved holidays

1. Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol. 2013 Jul;42(1):41-50.

2. FMF Certification of Biochemical Laboratories. Retrieved 22-2-2022 from https://fetalmedicine.com/fmf/FMF%20Certification%20of%20Biochemical%20Laboratories_new.pdf.